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Abstract
Background: Aging is marked by declines in levels of many sex hormones and growth factors, as well as
in cognitive function. The P300 event-related potential has been established as a predictor of cognitive
decline. We decided to determine if this measure, as well as 2 standard tests of memory and attention,
may be correlated with serum levels of sex hormones and growth factors, and if there are any
generalizations that could be made based on these parameters and the aging process.
Findings:  In this large clinically based preliminary study several sex-stratified associations between
hormone levels and cognition were observed, including (1) for males aged 30 to 49, both IGF-1 and IGFBP-
3 significantly associated negatively with prolonged P300 latency; (2) for males aged 30 to 49, the spearman
correlation between prolonged P300 latency and low free testosterone was significant; (3) for males aged
60 to 69, there was a significant negative correlation between P300 latency and DHEA levels; (4) for
females aged 50 to 59 IGFBP-3 significantly associated negatively with prolonged P300 latency; (5) for
females at all age periods, estrogen and progesterone were uncorrelated with P300 latency; and (6) for
females aged 40 to 69, there was significant negative correlation between DHEA levels and P300 latency.
Moreover there were no statistically significant correlations between any hormone and Wechsler Memory
Scale-III (WMS-111). However, in females, there was a significant positive correlation between estrogen
levels and the number of Attention Deficit Disorder (ADD) complaints.
Conclusion: Given certain caveats including confounding factors involving psychiatric and other chronic
diseases as well as medications, the results may still have important value. If these results could be
confirmed in a more rigorously controlled investigation, it may have important value in the diagnosis,
prevention and treatment of cognitive impairments and decline.
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Introduction
A review of the literature reveals that sex hormones have
often been associated with changes in behavioral and
mental abilities. As noted by Craig and Murphy, estrogen
may modulate brain function, and acute loss of ovarian
hormones increases neuronal membrane breakdown.
Additionally, suppression of ovarian function may reduce
activation of brain regions that are critical for memory [1].
Other research has shown that estrogen use may improve
mood amongst women with postnatal or perimenstrual
depression; however, it may contribute to increasing
depressive symptoms in women with premenstrual dys-
phoria [2]. Although it has yet to become widely accepted,
research has shown that estrogen replacement therapy
may help prevent Alzheimer's dementia [3].
The behavioral effects of the androgens testosterone and
dehydroepiandrosterone (DHEA) remain unclear but pre-
liminary reports suggest that their use is associated with
improved mood [4,5]. There is evidence that there is an
age-related testosterone depletion associated with the
development of Alzheimer disease [6]. At present, there is
not enough hard data to support the use of sex hormones
and DHEA, the adrenal androgen, for the treatment of
depression, cognitive decline or memory deficits.
The GH/insulin-like growth factor-1 (GH/IGF-1) axis is
known to be involved in aging of physiological functions
including low levels associating with cognitive decline as
a function of age [7]. Deficiency of growth hormone
(GH), an important regulator of IGF-1, is associated with
reduced wellbeing [8]. Furthermore, since plasma IGF-1
levels have been reported to be enhanced by DHEA
administration, it has been suggested that IGF-1 may have
a role in some of the reported associations between low
DHEA sulfate levels and impaired health measures in eld-
erly subjects [9].
Since there is sparse definitive information on hormone
plasma levels for measurement of cognitive decline as an
age-related process, we decided to investigate this issue.
Methods
Plasma sex and growth hormones (testosterone, DHEA,
estrogen, progesterone, GH and IGF-1) were analyzed in
both males and females across a wide age range and the
results were statistically correlated with an electroen-
cephalograph-obtained event-related potential (P300),
whose prolonged latency has been established as an accu-
rate predictor of cognitive and memory decline. The meth-
ods employed in this study were previously reported by
our laboratory [10]. Subjects also took the Wechsler Mem-
ory Scale (WMSIII) and the Test of Variables of Attention
(T.O.V.A.), which have been described in our previous
work [10].
Subjects
In this large (721 females and 654 males with an age range
of 30–93 years) clinically based study, all patients were
tested for their response to the P300 event-related poten-
tial (ERP) and screened for circulating hormones (testo-
sterone, progesterone, estrogen, dehydroepiandrosterone
(DHEA), and growth hormones IGF-1 and IGFBP-3).
Mean ± standard deviation of age for females was 57.4 ±
15.1 and 55.8 ± 14.5 for males.
Criteria for study inclusion
The patients had at least one P300 test. All test interpreters
were blinded to other patient results. These patients were
selected for study from an outpatient private medical clin-
ical practice (Medical and Neuropsychiatric) and research
foundation in New York City. All subjects signed an
approved IRB consent form based on an approval from
the PATH Medical IRB committee (registration #
IRB00002334). Subjects were made aware that their
results could be used in medical research and by signing
the informed consent, they volunteered to participate in
this study.
Plasma Analysis
Venipuncture was done in nonfasting subjects between
8:30 AM and 7:30 PM at baseline examination. Assays
were performed blinded to information on the subject.
Plasma levels of estradiol and sex hormone-binding glob-
ulin were estimated with double anti-body radioimmu-
noassays (Bioreference Lab, New York, New York). As
measures of the levels of bioavailable and free estradiol,
testosterone, DHEA, and nonprotein-bound estradiol,
respectively, were calculated on the basis of hormone and
binding protein levels. For the analysis of growth hor-
mone and insulin-like growth factor binding proteins the
laboratory performed standardized procedures. Free testo-
sterone, or unbound testosterone, was calculated by cor-
recting for SHBG and albumin.
BEAM Mapping
All patients in this study were analyzed by the Brain Elec-
trical Activity Map (BEAM), a computerized quantitative
EEG. A 24-channel EEG recorder was used. Standard tech-
niques were used to measure event-related P300 pro-
longed latency [10]. The standard International 10/20
System of electrode placement was used. In addition,
there were two on earlobes, two EKG electrodes connected
to the cervical spine and electrocap, and two supraorbital
electrodes (EOG) were also used. Digital EEG was
recorded in a monopolar (LR linked ears left over right)
and bipolar (LR 3,4 linked ears left over right) montage.
Waveforms were averaged off-line, such that trials on
which the EEG or EOG exceeded ± 100 microvolts were
rejected; single-trial data also were subjected to an EOG
correction procedure to remove any remaining artifact.BMC Research Notes 2009, 2:126 http://www.biomedcentral.com/1756-0500/2/126
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Statistics
As hormone levels are known to be influenced by sex, the
analysis was performed for females and males separately.
For females, IGF-1, IGFBP-3, estrogen, progesterone, and
DHEA were studied. For males, IGF-1, IGFBP-3, free testo-
sterone, and DHEA were studied. Since the study included
a broad spectrum of ages, the potential for the age factor
to confound the analysis of the complete data set com-
pelled an approach in which subjects were stratified by
age decade (i.e. 30 to 39, 40 to 49, etc.). This approach
helped to negate any influence that age might have on
P300 latency and hormone levels, since it has been previ-
ously established that the distribution of these measures
are not independent of age [10]. Also, levels of certain
hormones may be important diagnostically for specific
age groups, while, for other age groups, hormone variabil-
ity may be suppressed by the age factor. To ensure suffi-
cient sample size for each strata, the age groups selected
were 30 to 39 years, 40 to 49 years, 50 to 59 years, 60 to
69 years, and 70 and above, with a maximum age of 93
years. Within each age group, the sample lower quartile
(25th percentile) was obtained for each hormone level and
used as a cutpoint to define low hormone levels. The hor-
mone data was standardized by assigning a percentile
ranking of 1 to 20 to each hormone measure, with 1 rep-
resenting values ranging from the minimum to the 5th per-
centile and 20 representing values ranging from the 95th
percentile to the maximum. Partial correlations were per-
formed to check for associations between hormone rank-
ings and P300 latency controlling for age. As a
consequence of previous analyses, the subject's age plus
300 served as the cutpoint defining prolonged P300
latency for all subjects [10]. Using the cutpoints, contin-
gency table analysis was performed to determine if a dif-
ference in the percentage of subjects with low hormone
levels was observed for prolonged vs. normal P300
latency, with p < 0.05 for the Chi-square test considered
significant. To further substantiate possible associations
between P300 latency and hormone levels within an age
group, Spearman correlation was performed. If adjacent
age groups had similar results the age groups were com-
bined to obtain generalized results.
Results
While the amplitude of the P300 evoked potential was
assessed in this study we did not find any significant asso-
ciations. However, in terms of latency, significant associa-
tions included (1) in males aged 30 to 49, both IGF-1 (rho
= -0.357, p < 0.001) and IGFBP-3 (rho = -0.230, p ==
0.034) significantly associated negatively with prolonged
P300, and for all males, rank-transformed IGF-1 and
IGFBP-3 values were significantly correlated (r = 0.521, p
< 0.001) after partially out the age effect; (2) in males aged
30 to 49, the correlation between prolonged P300 latency
and low free testosterone (rho = -0.305, p = 0.004) was
significant; (3) in males aged 60 to 69, there was a signif-
icant negative correlation (rho = -0.345, p = 0.031)
between P300 latency and DHEA levels; (4) in females
aged 50 to 59, IGFBP-3 was significantly (rho = -0.239, p
= 0.040) negatively associated with prolonged P300
latency; (5) In females aged 40 to 69, there was nearly sig-
nificant (rho = -0.170, p = 0.050) negative correlation
between DHEA levels and P300 latency. Moreover, for all
females, there was a significant (rho = 0.352, p < 0.001)
positive correlation between estrogen levels and the
number of ADD complaints.
Discussion
As stated this is a preliminary investigation and future
studies will attempt to provide additional required infor-
mation to make any serious interpretation of the current
data. There are many caveats to this study that will provide
a blueprint for additional meaningful research. One
major problem in this study was the patient group being
not well defined due to constraints of the clinical data col-
lection center. While we are cognizant that a perspective
study utilizing only healthy volunteers is warranted, the
present study does have important value. With that stated
our concern is that underlying disease is a major con-
founding factor because of the presence of a psychiatric
disorder (as was the case for the majority of patients in
this study). Other clinical disorders of note, such as Alzhe-
imer's disease, diabetes mellitus, and chronic hepatic dis-
ease, among others, will affect the P300 measurements.
Another caveat is that it is well known that several medi-
cations (for instance oral contraceptives in females) and
also underlying diseases will influence measured hor-
mone levels. Thus in future studies we will attempt to sep-
arate patients with chronic diseases and assign categories
based on psychiatric disorders, and metabolic diseases
where baseline values may be outliers, or further con-
founded by medication. In addition recent data suggest
that head trauma is an important cause of pituitary dys-
function and also a well-known reason for cognitive dys-
function. In future studies the head trauma patients will
be excluded from the study group, or at least those that fall
into a <25th percentile. We are also cognizant of the rela-
tionship of body mass index (BMI) of the patients on hor-
mone levels. In that regard we have already collected data
on over 900 patients and evaluated the relationship
between growth factors and BMI as well as growth hor-
mone secretion. In future studies we intend to exclude all
patients with a BMI of >30. Moreover we are cognizant
that many studies only measure hormone levels in the
morning to avoid variation as a consequence of diurnal
rhythms. This potentially confounding factor must be
taken into account as another caveat of the present study.
Importantly this fact is particularly true for testosterone.BMC Research Notes 2009, 2:126 http://www.biomedcentral.com/1756-0500/2/126
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Considering these caveats, our results can be analyzed
with caution. In terms of the findings related to the female
sex hormone estrogen and the P300 latency results, the lit-
erature has not consistently shown that estrogens prevent
cognitive decline or Alzheimer's disease. In fact one study
showed a small negative effect of higher estradiol levels in
memory performance in both females and males and
other studies do not support a positive outcome with hor-
mone therapy [11]. In terms of the present study it is note-
worthy, that binding sites for GH and IGF-1 contribute to
the function of various brain areas. Their distribution sug-
gests that GH and IGF-1 contribute to the function of the
hippocampus, a brain structure important for the mainte-
nance of cognitive functions such as learning and memory
[12]. Evidence for cognitive deficits in GH-deficient indi-
viduals has been found in various studies, some of which
have shown that these deficits can be reversed by GH sub-
stitution therapy [13]. Based on available data, one might
hypothesize that relative GH or IGF-1 deficiency could
contribute to the deterioration of cognitive function
observed in the elderly. However, we cannot as yet pro-
vide an explanation for the differential gender findings
with regard to the fact that IGFBP-3 significantly associ-
ated with P300 latency in females but IGF-1 did not,
whereas both growth hormones significantly associated
with P300 prolonged latency in males. Evidently it
appears that both DHEA and free testosterone level nega-
tively correlate with prolonged P300 latency especially in
older men. Similar findings were obtained for DHEA lev-
els and prolonged P300 latency in older women. These
findings could have very significant importance in target-
ing both prevention and treatment of cognitive dysfunc-
tion in both males and females.
The present study also addressed attentional complaints
and the potential relation to hormone levels. Follow up to
this pilot study on attentional complaints further con-
firms the early findings. Attention problems have a multi-
modal dimension. ADHD, including attentional
complaints, is related to memory, electrophysiology, and
also to genetic and psychiatric factors. Attentional com-
plaints also have Advanced Psychiatric Disease Perform-
ance Test (Axis I) sources, such as anxiety disorders,
depression, schizophrenia, delusions, etc. It turns out that
attention deficits and impaired memory are common to
patients with depression [14]. The only hormone we
found in the present pilot study to significantly associate
with ADD complaints was estrogen. But it is also notewor-
thy that Lijffijt et al found that a reduction in attention-
related brain potential as measured on an EEG, as well as
marked selective attention impairments, were present in
patients with reduced levels of GH and IGF-1 [15].
Conclusion
The present study does not reject the possibility that exog-
enous estrogens, testosterone, DHEA, and growth hor-
mones may be beneficial in protecting against cognitive
decline. To our knowledge this is the first report showing
a significant negative association of IGFBP-3, free testo-
sterone and DHEA, with P300 prolonged latency (a pre-
dictor of memory impairment and cognitive decline) [10].
In addition, it is also the first report of a significant nega-
tive association of endogenous levels of estrogen and the
number of ADD complaints in a clinical setting. In sup-
port of these results two recent studies clearly demonstrate
that GH deficiency and low IGF-1 levels are associated
with prolonged P300 latency in both females and males
[16,17]. If these preliminary results could be confirmed, it
may have important value in the diagnosis, prevention
and treatment of early cognitive dysfunction.
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